Adenovirus-mediated anti insulin-like growth factor I gene transfer for the treatment of hepatocellular carcinoma

Anticancer Research

Volumn 22, Issue 6 C, 2002, Pages 3895-3904

  Lafarge Frayssinet, Christian ^a   Martin, Chantal ^b   Van Binh, Pascale Nguyen ^c   Achard Ellouk, Sophie ^b   Duc, Huynh T ^c   Frayssinet, Charles ^a   Cardoso, Georges ^d   Desauty, Genevieve ^a   Warnet, Jean Michel ^b   Bréchot, Christian ^d   Sarasin, Alain ^a  

^a INSTITUT ANDRÉ LWOFF   (France)

^b Centre Universitaire des Saints Pères   (France)

^c HÔPITAL PAUL BROUSSE   (France)

^d INSERM   (France)

Author keywords

Antisense IGF I; Gene therapy; Hepatocarcinoma; Recombinant adenovirus

Indexed keywords

ANTIBODY; SOMATOMEDIN C; SOMATOMEDIN C ANTIBODY; UNCLASSIFIED DRUG;

ADENOVIRUS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL CULTURE; CANCER REGRESSION; CARCINOGENESIS; CONTROLLED STUDY; EXPRESSION VECTOR; GENE TRANSFER; LIVER CELL CARCINOMA; NONHUMAN; PRIORITY JOURNAL; RAT; VIRUS RECOMBINANT;

EID: 0036876004     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Fresch ER, Schmid CHR, Schwander J and Zapf J: Actions of insulin-like growth factors. Ann Rev Physiol 47: 443-467, 1985.
2. White MF and Kahn CR: The insulin signaling system. J Biol Chem 269: 1-4, 1994.
3. Macaulay VM: Insulin-like growth factors and cancer. British J Cancer 65: 311-320, 1992.
4. Rho O, Bol DK, You J et al.: Altered expression of insulin-like growth factor I and its receptor during nultistage carcinogenosis in mouse skin. Mol carcinogenesis 17: 62-69, 1996.
5. Chan JM, Stampfer MJ, Giovannuci E et al.: Plasma insulin-like growth factor I and prostate cancer risk: A prospective study. Science 279: 563-566, 1998.
6. Lee AV, Hilsenberk SG and Yee D: IGF system components as prognostic markers in breast cancer. Breast Cancer Research and Treatment 47: 295-302, 1998.
7. Heaton JH, Krett NL and Gelehrter TD: Regulation of insulin and insulin-like growth factor (IGF) responsivness by IGFI's in rat hepatoma cells. Endocrinology 118: 2555-2561, 1986.
8. Lafarge-Frayssinet C, Duc HT, Frayssinet C et al.: Antisense insulin-like growth factor I transferred into a rat hepatoma cell line inhibits tumorigenesis by modulating major histocompatibility complex I cell surface expression. Cancer Gene Therapy 4: 276-285, 1997.
9. Ellouk-Achard S, Djenabi S, De Oliveira GA et al.: Induction of apoptosis in rat hepatocarcinoma cells by expression of IGF-I antisense c-DNA. J Hepatol 29: 807-818, 1998.
10. Trojan J, Blossey BK, Johnson TR et al.: Loss of tumorigenisity of rat glioblastoma directed by episome-based antisense cDNA transcription of insulin-ike growth factor I Proc Natl Acad Sci USA 89: 4874-4878, 1992.
11. Trojan J, Johnson TR, Rudin SD et al.: Treatment and prevention of rat glioblastoma by immunogenic C6 cells expressing antisense insulin-like growth factor I RNA. Science 259: 94-96, 1993.
12. Trojan J, Jonhson TR, Rudin SD et al.: Gene therapy of murine teratocarcinoma: Separate functions for insulin-like growth factors I and II in immunogenicity and differentiation. Proc Natl Acad Sci USA 91: 6088-6092, 1994.
13. Resnicoff M, Sell C, Rubini M et al.: Rat glioblastoma cells expressing an antisense RNA to the insulin-like growth factor I (IGF I) receptor are non tumorigenic and induce regression of wild-type tumors. Cancer Res 54: 2218-2222, 1994.
14. Hitt M, Addison C and Graham FL: Human adenovirus vectors for gene transfer into mammalian cells. Adv Pharmacol 40: 137-206, 1997.
15. Hatzfeld AB, Feldman G, Guesnon J et al.: The location of aldolase A, B by immunoperoxidase technique in fast growing rat hepatomas. Cancer Res 38: 16-22, 1978.
16. Laferge-Frayssinet C, Cassingena R, Frayssinet C et al.: Polyamine content and oncogene expression in hepatoma cell in culture during methionine deprivation and refeeding. Anticancer Res 13: 491-496, 1993.
17. Trojan J, uriel J, Deugnien MA and Gaillard J: Immunocytochemical quantitative study of alphafetoprotein in normal and neoplastic developement. Dev Neurosci 6: 521-529, 1984.
18. Statford-Perricaudet LD, Makeh I, Perricaudet M and Briand P: Wide spread long term gene transfer to mouse skeletal muscles and heart. J Clin Invest 90: 626-630, 1992.
19. Duc HT, Rucay P, Righenzi S et al.: Monoclonal antibodies directed against T cells epitopes presented by class I MHC antigens. Int Immunology 5: 427-431, 1993.
20. Vile RG and Hart IR: Use of tissue-specific expression of the herpes simplex virus thymidine kinase gene to inhibit growth of established murine melanomas following direct intratumoral injection of DNA. Cancer Res 53: 3860-3864, 1993.
21. Varner J and Cheresh S: Integrins and cancer. Curr Opin Cell Biol 8: 724-730, 1996.
22. Brigham KL, Meyrick B, Christman B et al.: In vivo transfection of murine lungs with a functioning prokariotic gene using a liposome vehicle. Am J Med Sci 298: 278-281, 1989.
23. Hamel Y, Lacoste J, Frayssinet C et al.: Inhibition of gene expression by anti-sense C-5 propyne oligonucleotides detected by a reporter enzyme. Biochem J 339: 547-553, 1999.
24. Gerolami R, Cardoso J, Bralet M et al.: Enhanced in vivo adenovirus-mediated gene transfer to rat hepatocarcinomas by selective administration into hepatic artery. Gene Therapy 5: 896-904, 1998.
25. Smaglik P: Tighten watch urged on adenoviral vectors. Nature 402: 305, 1999.
26. Lee CT, Wu S, Gabrilovitch D et al.: Antiturnor effects of an adenovirus expressing antisense insulin-like growth factor I receptor on human lung cancer cell lines. Cancer Res 56: 3038-3041, 1996.